MUMBAI (Reuters) - Cadila Healthcare Ltd has received a U.S. Food and Drug Administration (FDA) warning letter for violating manufacturing standards at two of its production facilities, the latest in ...

The manufacturing issues continue to mount for India’s Cadila Healthcare. The drugmaker, which last year was hit with an FDA warning letter for two of its Indian plants, is now recalling several ...

Cadila Healthcare, also known as Zydus Cadila, is about to start a phase three clinical trial for a potential coronavirus vaccine on roughly 30,000 volunteers, chairman Pankaj Patel told CNBC. The ...

AHMEDABAD (Reuters) - India's Cadila Healthcare is aiming to triple monthly production of a COVID-19 vaccine candidate to as many as 30 million doses, its managing director said on Monday, as the ...

The FDA is continuing its efforts to raise the standards of India's pharma industry, closing out the year with a warning to Cadila Healthcare, the company acknowledged in a report to the Bombay Stock ...

BENGALURU (Reuters) - India's Cadila Healthcare Ltd has received restricted emergency use approval from local regulators to use a Hepatitis C drug as a treatment for moderate COVID-19 in adults, the ...

Get all latest & breaking news on Cadila Pharmaceuticals Ltd. Watch videos, top stories and articles on Cadila Pharmaceuticals Ltd at moneycontrol.com.

Zydus Cadila said on Saturday the company would start delivering the Covid-19 vaccines from mid-September. The company will be ramping up capacity and be able to deliver one crore vaccines per month ...

The drug is manufactured at the Zydus group's injection manufacturing facility in Ahmedabad and will be launched commercially within the US market immediately. (Representational image) Drug firm Zydus ...

New Delhi: Drug firm Zydus Cadila on Friday said it has received approval from the US health regulator to market Pemetrexed injection, used to treat certain kinds of cancers, in the American market.